SD 169 (Synonyms: 5-Carbamoylindole) |
Catalog No.GC14982
One-Click Copy Product Info
|
selective ATP competitive inhibitor of the MAP kinases p38α and p38β
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1670-87-7
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
SD 169 (indole-5-carboxamide) is a selective and ATP competitive inhibitor of the MAP kinases p38α and p38β [1].
The p38 mitogen-activated protein kinases are a class of mitogen-activated protein kinases (MAPKs) that are responsive to stress stimuli, such as cytokines, ultraviolet irradiation, heat shock, and osmotic shock, and are involved in regulating inflammatory cytokine production, modulating T cell function and cell differentiation, apoptosis and autophagy [1].
SD-169 significantly reduced p38 and HSP60 expression in T cells of the pancreatic beta islets. SD-169 treatment significantly lowered the incidence of diabetes as determined by blood glucose levels. In NOD mice, SD-169 treatment significantly reduced immuno-histochemistry of pancreatic beta islet tissue in CD5+ T cell infiltration. In mildly and moderately hyperglycemic NOD mice, SD-169 (600 mg/kg) treatment lowered blood glucose and improved glucose homeostasis. SD-169 prevented the development and progression of diabetes in NOD mice by inhibiting T cell infiltration and activation, thereby preserving beta cell mass via inhibition of the p38 MAPK signaling pathway. SD 169 also reduced the incidence of diabetes, lowered blood glucose, and improved glucose homeostasis [1]. Gavage administration o SD-169 (30 mg/kg) significantly increased the rate of axonal regeneration in animals with crush injury. SD-169 significantly reduced TNF-mediated primary SC death in culture experiments. SD-169 promoted axonal regeneration through interactions with SC signaling and TNF activity [2].
References:
[1] Medicherla S, Protter A A, Ma J Y, et al. Preventive and therapeutic potential of p38α-selective mitogen-activated protein kinase inhibitor in nonobese diabetic mice with Type 1 diabetes[J]. Journal of Pharmacology and Experimental Therapeutics, 2006, 318(1): 99-107.
[2] Myers R R, Sekiguchi Y, Kikuchi S, et al. Inhibition of p38 MAP kinase activity enhances axonal regeneration[J]. Experimental neurology, 2003, 184(2): 606-614.
| Cas No. | 1670-87-7 | SDF | |
| Synonyms | 5-Carbamoylindole | ||
| Chemical Name | 1H-indole-5-carboxamide | ||
| Canonical SMILES | NC(C1=CC=C(NC=C2)C2=C1)=O | ||
| Formula | C9H8N2O | M.Wt | 160.2 |
| Solubility | ≤1.4mg/ml in ethanol;5mg/ml in DMSO;16mg/ml in dimethyl formamide | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 6.2422 mL | 31.211 mL | 62.422 mL |
| 5 mM | 1.2484 mL | 6.2422 mL | 12.4844 mL |
| 10 mM | 624.2 μL | 3.1211 mL | 6.2422 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >99.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 14 reference(s) in Google Scholar.)